About Michael Keane
Michael Keane is a president and director at Aspicio Therapeutics.
Michael Keane first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Keane in the role, so the role may have started earlier or lasted longer.
Aspicio Therapeutics, Inc.
President and director
2024 – 2026 · Downingtown, PA
Develops a biologic therapy for people with vision loss from dry age-related macular degeneration.